Cargando…
Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer
Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins neutrophil gelatinase associated lipocalin...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562325/ https://www.ncbi.nlm.nih.gov/pubmed/23383312 http://dx.doi.org/10.1371/journal.pone.0055171 |
_version_ | 1782258079475171328 |
---|---|
author | Kaur, Sukhwinder Chakraborty, Subhankar Baine, Michael J. Mallya, Kavita Smith, Lynette M. Sasson, Aaron Brand, Randall Guha, Sushovan Jain, Maneesh Wittel, Uwe Singh, Shailender K. Batra, Surinder K. |
author_facet | Kaur, Sukhwinder Chakraborty, Subhankar Baine, Michael J. Mallya, Kavita Smith, Lynette M. Sasson, Aaron Brand, Randall Guha, Sushovan Jain, Maneesh Wittel, Uwe Singh, Shailender K. Batra, Surinder K. |
author_sort | Kaur, Sukhwinder |
collection | PubMed |
description | Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins neutrophil gelatinase associated lipocalin (NGAL) and TGF-β family member macrophage inhibitory cytokine-1 (MIC-1) are proposed as most potential biomarkers specifically elevated in the blood of PC patients. However, their performance as diagnostic markers for PC, particularly in pre-treatment patients, remains unknown. In order to evaluate the diagnostic efficacy of NGAL and MIC-1, their levels were measured in plasma samples from patients with pre-treatment PC patients (n = 91) and compared it with those in healthy control (HC) individuals (n = 24) and patients with chronic pancreatitis (CP, n = 23). The diagnostic performance of these two proteins was further compared with that of CA19-9, a tumor marker commonly used to follow PC progression. The levels of all three biomarkers were significantly higher in PC compared to HCs. The mean (± standard deviation, SD) plasma NGAL, CA19-9 and MIC-1 levels in PC patients was 111.1 ng/mL (2.2), 219.2 U/mL (7.8) and 4.5 ng/mL (4.1), respectively. In comparing resectable PC to healthy patients, all three biomarkers were found to have comparable sensitivities (between 64%-81%) but CA19-9 and NGAL had a higher specificity (92% and 88%, respectively). For distinguishing resectable PC from CP patients, CA19-9 and MIC-1 were most specific (74% and 78% respectively). CA19-9 at an optimal cut-off of 54.1 U/ml is highly specific in differentiating resectable (stage 1/2) pancreatic cancer patients from controls in comparison to its clinical cut-off (37.1 U/ml). Notably, the addition of MIC-1 to CA19-9 significantly improved the ability to distinguish resectable PC cases from CP (p = 0.029). Overall, MIC-1 in combination with CA19-9 improved the diagnostic accuracy of differentiating PC from CP and HCs. |
format | Online Article Text |
id | pubmed-3562325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35623252013-02-04 Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer Kaur, Sukhwinder Chakraborty, Subhankar Baine, Michael J. Mallya, Kavita Smith, Lynette M. Sasson, Aaron Brand, Randall Guha, Sushovan Jain, Maneesh Wittel, Uwe Singh, Shailender K. Batra, Surinder K. PLoS One Research Article Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins neutrophil gelatinase associated lipocalin (NGAL) and TGF-β family member macrophage inhibitory cytokine-1 (MIC-1) are proposed as most potential biomarkers specifically elevated in the blood of PC patients. However, their performance as diagnostic markers for PC, particularly in pre-treatment patients, remains unknown. In order to evaluate the diagnostic efficacy of NGAL and MIC-1, their levels were measured in plasma samples from patients with pre-treatment PC patients (n = 91) and compared it with those in healthy control (HC) individuals (n = 24) and patients with chronic pancreatitis (CP, n = 23). The diagnostic performance of these two proteins was further compared with that of CA19-9, a tumor marker commonly used to follow PC progression. The levels of all three biomarkers were significantly higher in PC compared to HCs. The mean (± standard deviation, SD) plasma NGAL, CA19-9 and MIC-1 levels in PC patients was 111.1 ng/mL (2.2), 219.2 U/mL (7.8) and 4.5 ng/mL (4.1), respectively. In comparing resectable PC to healthy patients, all three biomarkers were found to have comparable sensitivities (between 64%-81%) but CA19-9 and NGAL had a higher specificity (92% and 88%, respectively). For distinguishing resectable PC from CP patients, CA19-9 and MIC-1 were most specific (74% and 78% respectively). CA19-9 at an optimal cut-off of 54.1 U/ml is highly specific in differentiating resectable (stage 1/2) pancreatic cancer patients from controls in comparison to its clinical cut-off (37.1 U/ml). Notably, the addition of MIC-1 to CA19-9 significantly improved the ability to distinguish resectable PC cases from CP (p = 0.029). Overall, MIC-1 in combination with CA19-9 improved the diagnostic accuracy of differentiating PC from CP and HCs. Public Library of Science 2013-02-01 /pmc/articles/PMC3562325/ /pubmed/23383312 http://dx.doi.org/10.1371/journal.pone.0055171 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Kaur, Sukhwinder Chakraborty, Subhankar Baine, Michael J. Mallya, Kavita Smith, Lynette M. Sasson, Aaron Brand, Randall Guha, Sushovan Jain, Maneesh Wittel, Uwe Singh, Shailender K. Batra, Surinder K. Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer |
title | Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer |
title_full | Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer |
title_fullStr | Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer |
title_full_unstemmed | Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer |
title_short | Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer |
title_sort | potentials of plasma ngal and mic-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562325/ https://www.ncbi.nlm.nih.gov/pubmed/23383312 http://dx.doi.org/10.1371/journal.pone.0055171 |
work_keys_str_mv | AT kaursukhwinder potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT chakrabortysubhankar potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT bainemichaelj potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT mallyakavita potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT smithlynettem potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT sassonaaron potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT brandrandall potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT guhasushovan potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT jainmaneesh potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT witteluwe potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT singhshailenderk potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT batrasurinderk potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer |